Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC
Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.
Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors
Moderna Unveils COVID-19 Booster Data As Pfizer Goes Before Skeptical Regulators
Moderna is hot on the heels of Pfizer with booster data for its COVID-19 vaccine, and could benefit from its rival being first to face potential skepticism from the US FDA over booster data for its vaccine.
UK Chooses Pfizer And Moderna For COVID-19 Boosters, But Questions Remain On Unpublished Trial Data
The UK’s choice of the mRNA vaccines as COVID-19 boosters is no surprise – but not releasing the key study data behind the decision is.
Five Prime Founder Rusty Williams Returns With Walking Fish Therapeutics
Named after a remarkable self-regenerating salamander, the new San Francisco biotech aims to unlock the potential of B-cells to be “in vivo protein factories”.